Implementing Palopegteriparatide in Practice: Transition Protocols, Monitoring, and Reproductive Counseling

Transitioning from conventional calcium and active vitamin D therapy to palopegteriparatide requires a structured approach and clear patient counseling. In this portion of the HCPLive Special Report, Sara Lubitz, MD, explains that while she views most individuals without endogenous PTH as potential candidates for PTH replacement, the initial dose-finding phase can be demanding. After adjustments in calcium, active vitamin D, or palopegteriparatide doses, patients typically require laboratory monitoring every 7 to 10 days, with more frequent testing if symptoms of hypo- or hypercalcemia occur.

Lubitz stresses the importance of setting expectations and aligning the timing of transition with the patient’s personal and professional circumstances. She advises clinicians to select periods when patients can reliably attend laboratory appointments and manage potential symptom fluctuations, and to avoid intervals surrounding major surgery, extensive travel, or other disruptive events.

Some patients may find that summer breaks or times of reduced work obligations are optimal for initiating therapy. In her experience, patients who complete this transition generally regard the short-term inconvenience as worthwhile, and they overwhelmingly prefer to remain on palopegteriparatide rather than return to conventional regimens.

Special populations, particularly women of childbearing age, require additional counseling. Lubitz notes that robust safety data for PTH analogs, including palopegteriparatide, during pregnancy and lactation are currently lacking. She recommends proactive discussions about reproductive planning and emphasizes that, at present, patients are typically transitioned back to conventional calcium and vitamin D therapy when a planned pregnancy is anticipated. Clear communication about these limitations and a shared decision-making framework are essential to balancing potential maternal and fetal risks with the benefits of continued PTH replacement.